Discounted Cash Flow (DCF) Analysis Unlevered

Therapix Biosciences Ltd.

Therapix Biosciences Ltd. (TRPX)

$0.317
-0.313 (-49.68%)

Operating Data

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue --------
Revenue (%)
EBITDA --------
EBITDA (%)
EBIT --------
EBIT (%)
Depreciation --------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Total Cash --------
Total Cash (%)
Account Receivables --------
Account Receivables (%)
Inventories --------
Inventories (%)
Accounts Payable --------
Accounts Payable (%)
Capital Expenditure --------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.317
Beta 0.184
Diluted Shares Outstanding 0.06
Cost of Debt
Tax Rate 5.39
After-tax Cost of Debt 4.73%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.926
Total Debt 0.87
Total Equity 0.02
Total Capital 0.89
Debt Weighting 97.97
Equity Weighting 2.03
Wacc

Build Up Free Cash

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue --------
EBITDA --------
EBIT --------
Tax Rate 0.00%5.39%2.70%2.70%2.70%2.70%2.70%2.70%
EBIAT --------
Depreciation --------
Accounts Receivable --------
Inventories --------
Accounts Payable --------
Capital Expenditure -0.04-0.02-0.00-----
UFCF --------
WACC
PV UFCF --------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 4.71
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -1.49
Equity Value -
Shares Outstanding 0.06
Equity Value Per Share -